title: What was wrong and might now go right with clinical trials for lupus?
authors.affiliation: Clinical Pharmacology Research Program, University of Oklahoma Health Sciences Center, Oklahoma Medical Research, Oklahoma City, OK 73104, USA. joan-merrill@omrf.org
authors.forename: Joan T
authors.initials: JT
authors.lastname: Merrill
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000592:standards*; D017326:Clinical Trials, Phase III as Topic / Q000592:standards*; D017277:Drug Approval; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D012107:Research Design / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents
references.citation: Clin Exp Rheumatol. 2000 Sep-Oct;18(5):565-70
references.pmid: 11072595
references.citation: Curr Rheumatol Rep. 2002 Aug;4(4):345-50
references.pmid: 12126587
references.citation: Cytokine. 1998 Feb;10(2):140-7
references.pmid: 9512904